|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Ajani JA, Barthel JS, Bekaii-Saab T, et
al: NCCN Gastric Cancer Panel: Gastric cancer. J Natl Compr Canc
Netw. 8:378–409. 2010.
|
|
4
|
Park do J, Kong SH, Lee HJ, et al:
Subclassification of pT2 gastric adenocarcinoma according to depth
of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery.
141:757–763. 2007.PubMed/NCBI
|
|
5
|
Liu X, Xu Y, Long Z, Zhu H and Wang Y:
Prognostic significance of tumor size in T3 gastric cancer. Ann
Surg Oncol. 16:1875–1882. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bretscher PA: A two-step, two-signal model
for the primary activation of precursor helper T cells. Proc Natl
Acad Sci USA. 96:185–190. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chambers CA and Allison JP: Costimulatory
regulation of T cell function. Curr Opin Cell Biol. 11:203–210.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chambers CA, Kuhns MS, Egen JG and Allison
JP: CTLA-4-mediated inhibition in regulation of T cell responses:
mechanisms and manipulation in tumor immunotherapy. Annu Rev
Immunol. 19:565–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barber DL, Wherry EJ, Masopust D, et al:
Restoring function in exhausted CD8 T cells during chronic viral
infection. Nature. 439:682–687. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peggs KS, Quezada SA and Allison JP: Cell
intrinsic mechanisms of T-cell inhibition and application to cancer
therapy. Immunol Rev. 224:141–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ha SJ, West EE, Araki K, Smith KA and
Ahmed R: Manipulating both the inhibitory and stimulatory immune
system towards the success of therapeutic vaccination against
chronic viral infections. Immunol Rev. 223:317–333. 2008.
View Article : Google Scholar
|
|
12
|
Blackburn SD, Shin H, Haining WN, et al:
Coregulation of CD8+ T cell exhaustion by multiple
inhibitory receptors during chronic viral infection. Nat Immunol.
10:29–37. 2009.PubMed/NCBI
|
|
13
|
Topalian SL, Hodi FS, Brahmer JR, et al:
Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hodi FS, O’Day SJ, McDermott DF, et al:
Improved survival with ipilimumab in patients with metastatic
melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
|
|
15
|
Eggermont AM and Robert C: New drugs in
melanoma: it’s a whole new world. Eur J Cancer. 47:2150–2157.
2011.
|
|
16
|
Brahmer JR, Tykodi SS, Chow LQ, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolchok JD, Kluger H, Callahan MK, et al:
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med.
369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe N, Gavrieli M, Sedy JR, et al:
BTLA is a lymphocyte inhibitory receptor with similarities to
CTLA-4 and PD-1. Nat Immunol. 4:670–679. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sedy JR, Gavrieli M, Potter KG, et al: B
and T lymphocyte attenuator regulates T cell activation through
interaction with herpesvirus entry mediator. Nat Immunol. 6:90–98.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonzalez LC, Loyet KM, Calemine-Fenaux J,
et al: A coreceptor interaction between the CD28 and TNF receptor
family members B and T lymphocyte attenuator and herpesvirus entry
mediator. Proc Natl Acad Sci USA. 102:1116–1121. 2005. View Article : Google Scholar
|
|
21
|
Derré L, Rivals JP, Jandus C, et al: BTLA
mediates inhibition of human tumor-specific CD8+ T cells
that can be partially reversed by vaccination. J Clin Invest.
120:157–167. 2010.
|
|
22
|
Fu Z, Li D, Jiang W, et al: Association of
BTLA gene polymorphisms with the risk of malignant breast cancer in
Chinese women of Heilongjiang Province. Breast Cancer Res Treat.
120:195–202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer (UICC) TNM classification of
malignant tumours. 7. New York: Wiley-Liss; 2010
|
|
24
|
Japanese Gastric Cancer Association.
Japanese Classification of Gastric Carcinoma - 2nd English Edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ajani JA, Barthel JS, Bekaii-Saab T, et
al: NCCN Gastric Cancer Panel: Gastric cancer. J Natl Compr Canc
Netw. 8:378–409. 2010.
|
|
26
|
Wang W, Lv L, Pan K, et al: Reduced
expression of transcription factor AP-2α is associated with gastric
adenocarcinoma prognosis. PLoS One. 6:e248972011.
|
|
27
|
Gavrieli M, Sedy J, Nelson CA and Murphy
KM: BTLA and HVEM cross talk regulates inhibition and
costimulation. Adv Immunol. 92:157–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salvi S, Fontana V, Boccardo S, et al:
Evaluation of CTLA-4 expression and relevance as a novel prognostic
factor in patients with non-small cell lung cancer. Cancer Immunol
Immunother. 61:1463–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Contardi E, Palmisano GL, Tazzari PL, et
al: CTLA-4 is constitutively expressed on tumor cells and can
trigger apoptosis upon ligand interaction. Int J Cancer.
117:538–550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao H, Zhang L, Yang Y, et al: New
insights of CTLA-4 into its biological function in breast cancer.
Curr Cancer Drug Targets. 10:728–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhuang X, Zhang X, Xia X, et al: Ectopic
expression of TIM-3 in lung cancers: a potential independent
prognostic factor for patients with NSCLC. Am J Clin Pathol.
137:978–985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong J, Li J, Liu SM, et al:
CD33+/p-STAT1+ double-positive cell as a
prognostic factor for stage IIIa gastric cancer. Med Oncol.
30:4422013.
|
|
33
|
Fourcade J, Sun Z, Pagliano O, et al:
CD8(+) T cells specific for tumor antigens can be rendered
dysfunctional by the tumor microenvironment through upregulation of
the inhibitory receptors BTLA and PD-1. Cancer Res. 72:887–896.
2012. View Article : Google Scholar
|
|
34
|
Pasero C and Olive D: Interfering with
coinhibitory molecules: BTLA/HVEM as new targets to enhance
anti-tumor immunity. Immunol Lett. 151:71–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
